Application of levistilide A in preparation of anti-influenza virus drugs
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- LANZHOU UNIV
- Filing Date
- 2026-04-23
- Publication Date
- 2026-05-26
AI Technical Summary
Existing antiviral drugs for influenza face the problems of easy viral mutation and high risk of drug resistance, especially for influenza A virus, where there is a lack of broad-spectrum antiviral drugs to effectively control newly emerging and re-emerging viral infectious diseases.
Using angelica lactone A as the active ingredient, it inhibits the replication of H1N1 virus by suppressing the early internalization stage of the influenza virus life cycle, especially by binding to the influenza virus HA protein and blocking trypsin cleavage of HA0.
Angelica lactone A significantly inhibited H1N1 virus infection, improved cytopathic effects, reduced viral load, increased mouse survival rate, and alleviated lung tissue pathological damage, demonstrating significant in vitro and in vivo anti-influenza virus activity.
Smart Images

Figure CN122075477A_ABST